Unique ID issued by UMIN | UMIN000009503 |
---|---|
Receipt number | R000011168 |
Scientific Title | The retrospective study as the 1st-line chemotherapy of fluorouracil and bevacizumab for the frail-patients with unresectable or metastatic colorectal cancer |
Date of disclosure of the study information | 2012/12/07 |
Last modified on | 2012/12/07 23:25:53 |
The retrospective study as the 1st-line chemotherapy of fluorouracil and bevacizumab for the frail-patients with unresectable or metastatic colorectal cancer
The retrospective study of fluorouracil and bevacizumab for the frail-patients with colorectal cancer
The retrospective study as the 1st-line chemotherapy of fluorouracil and bevacizumab for the frail-patients with unresectable or metastatic colorectal cancer
The retrospective study of fluorouracil and bevacizumab for the frail-patients with colorectal cancer
Japan |
colorectal cancer
Gastroenterology | Hematology and clinical oncology | Adult |
Malignancy
NO
the safety and efficacy of chemotherapy combined bevacizumab with fluoropyrimidine for elderly or frail patients with unresectable or metastatic colorectal cancer
Safety,Efficacy
PFS, OS, RR, DCR, Adverse event
Observational
65 | years-old | <= |
Not applicable |
Male and Female
aged 65 years or older with a performance status (PS) of 0-2 and met one or more of the following conditions: Serum albumin< 3.5 g/dl, past medical history of radiation of the abdominal region or pelvic cavity, and incompatibility with oxaliplatin and irinotecan
None
26
1st name | |
Middle name | |
Last name | Masahiro Goto |
Osaka Medical College Hospital
Cancer Chemotherapy Center
2-7 Daigakumachi Takatsuki, Osaka 569-8686, JAPAN
1st name | |
Middle name | |
Last name |
Osaka Medical College Hospital
Cancer Chemotherapy Center
ctc004@poh.osaka-med.ac.jp
Osaka Medical College Hospital
Osaka Medical College Hospital
Other
NO
2012 | Year | 12 | Month | 07 | Day |
Partially published
No longer recruiting
2012 | Year | 01 | Month | 01 | Day |
2012 | Year | 01 | Month | 01 | Day |
Twenty-six patients diagnosed with unresectable or metastatic colorectal cancer at our hospital between October 2007 and December 2010 in whom treatment was started chemotherapy combined bevacizumab with S-1 or 5FU/LV (modified Roswell Park Memorial Institute (RPMI) regimen) were retrospectively investigated.
PFS was defined as the time between the days on which consent for treatment initiation was obtained and disease progression was confirmed. When disease progression could not be confirmed, it was defined as the time until death. OS was defined as the time between the treatment initiation and death, and, when death could not be confirmed, it was defined as the time until the final confirmation of survival. PFS and OS were analyzed employing the Kaplan-Meier method.
2012 | Year | 12 | Month | 07 | Day |
2012 | Year | 12 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011168
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |